INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,714 | +3.5% | 52,499 | +1.0% | 0.01% | 0.0% |
Q1 2024 | $3,589 | -5.3% | 51,997 | 0.0% | 0.01% | -12.5% |
Q4 2023 | $3,791 | +72.9% | 51,997 | +26.8% | 0.01% | +60.0% |
Q3 2023 | $2,192 | -10.9% | 40,997 | +2.5% | 0.01% | -16.7% |
Q2 2023 | $2,461 | +27.5% | 40,000 | +14.3% | 0.01% | +20.0% |
Q1 2023 | $1,930 | +4.6% | 35,000 | 0.0% | 0.01% | 0.0% |
Q4 2022 | $1,846 | -99.9% | 35,000 | -19.0% | 0.01% | -16.7% |
Q3 2022 | $1,926,000 | -22.4% | 43,219 | -0.8% | 0.01% | -14.3% |
Q2 2022 | $2,483,000 | -8.6% | 43,583 | -2.1% | 0.01% | 0.0% |
Q1 2022 | $2,717,000 | +67.2% | 44,500 | +39.9% | 0.01% | +75.0% |
Q4 2021 | $1,625,000 | +48.4% | 31,800 | +2.9% | 0.00% | +33.3% |
Q3 2021 | $1,095,000 | -9.3% | 30,900 | 0.0% | 0.00% | -25.0% |
Q2 2021 | $1,207,000 | +21.6% | 30,900 | 0.0% | 0.00% | +33.3% |
Q1 2021 | $993,000 | +4.2% | 30,900 | 0.0% | 0.00% | -25.0% |
Q4 2020 | $953,000 | +17.5% | 30,900 | -4.6% | 0.00% | 0.0% |
Q3 2020 | $811,000 | +64.5% | 32,400 | -50.7% | 0.00% | +33.3% |
Q3 2019 | $493,000 | -70.5% | 65,700 | -50.0% | 0.00% | -62.5% |
Q2 2019 | $1,670,000 | -14.1% | 131,400 | +47.8% | 0.01% | -33.3% |
Q1 2019 | $1,945,000 | +124.1% | 88,900 | +11.5% | 0.01% | +100.0% |
Q4 2018 | $868,000 | -55.4% | 79,700 | -10.3% | 0.01% | -45.5% |
Q3 2018 | $1,945,000 | +43.5% | 88,900 | +16.7% | 0.01% | +22.2% |
Q2 2018 | $1,355,000 | -69.1% | 76,200 | -64.3% | 0.01% | -70.0% |
Q1 2018 | $4,386,000 | +30.8% | 213,200 | -26.3% | 0.03% | +15.4% |
Q4 2017 | $3,352,000 | 0.0% | 289,200 | 0.0% | 0.03% | 0.0% |
Q3 2017 | $3,352,000 | -8.6% | 289,200 | 0.0% | 0.03% | -10.3% |
Q2 2017 | $3,667,000 | -5.7% | 289,200 | +20.9% | 0.03% | -19.4% |
Q1 2017 | $3,889,000 | +2409.0% | 239,200 | +2292.0% | 0.04% | +1700.0% |
Q4 2016 | $155,000 | -94.6% | 10,000 | -86.8% | 0.00% | -93.8% |
Q2 2016 | $2,845,000 | – | 76,000 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |